TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21390576
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine therapy for activating blood and dredging collaterals (ABDC)
Study: 21390576
Drug: Western medical
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medical conventional treatment for anti‐inflammation and immunosuppression
Study: 17230495
Drug: Psychotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy and relaxation in addition to standardized glucocorticoid therapy
Study: 17230495
Drug: Standardized glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized glucocorticoid therapy (Control)
Study: 11333065
Drug: Lithium 20
Normalized name: thenoate lithium 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium 20 mg/kg/day
Study: 3946364
Drug: Mylanta II
Normalized name: Mylanta II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mylanta II 30 ml/h through a nasogastric tube to a maximum of 90 ml/h
Study: 31979283
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of Eleutherococcus senticosus (ES) and Drynaria fortunei (DR) extracts for 12 weeks
Study: 31979283
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of ES and DR extracts
Study: 1458667
Drug: 0.125% amorolfine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% amorolfine cream
Study: 1458667
Drug: 0.5% amorolfine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% amorolfine cream
Study: 31112677
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen 60 minutes before surgery
Study: 31112677
Drug: IV placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV placebo (100 mL of saline) before surgery
Study: 31112677
Drug: IV placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV placebo (100 mL of saline) before and after surgery
Study: 31112677
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen 60 minutes after surgery
Study: 30407151
Drug: Oral steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroids (20 mg for ages 2-5 years, 30 mg for ages 6-8 years)
Study: 10376113
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg dehydroepiandrosterone
Study: 10376113
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg dehydroepiandrosterone
Study: 2064115
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg prednisone daily (n = 8)
Study: 2064115
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily (n = 8)
Study: 25706340
Drug: Collaborative centralized
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative centralized (CC) reminder/recall notifications
Study: 25706340
Drug: Collaborative centralized
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative centralized (CC) reminder/recall notifications endorsed by primary care practices
Study: 19947568
Drug: Dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen trometamol (25 mg, tid) + terazosin (2 mg, qn)
Study: 19947568
Drug: Indometacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin (25 mg, tid) + terazosin (2 mg, qn)
Study: 19947568
Drug: Terazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (2 mg, qn)
Study: 31479863
Drug: Alcohol (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.6 g/kg)
Study: 11981385
Drug: Prednisone (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (80 mg/d for 4 d, then tapered over 8 d) with valacyclovir (1 g, 3 times a day for 10 days)
Study: 2012351
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy for patients older than 65 years
Study: 7046318
Drug: Sclerosant injection
Normalized name: SCLEROSING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclerosant injection
Study: 28905189
Drug: Bortezomib (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1.3 mg/m2) and Dexamethasone (20 mg)
Study: 28905189
Drug: Bortezomib-Dexamethasone plus
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib-Dexamethasone plus Oral Cyclophosphamide (50 mg)
Study: 26111665
Drug: McGRATH MAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: McGRATH MAC laryngoscope (McG group)
Study: 23749315
Drug: TENS (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS (30 min, twice a week for 12 weeks)
Study: 23749315
Drug: TENS +
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS + Oxybutynin (multimodal treatment for 12 weeks)
Study: 10091202
Drug: Oral 17
Normalized name: polyoxypropylene (17)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 17 beta‐estradiol, 2 mg/day for 3 months
Study: 11247619
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitor (SSRI) medication
Study: 29602978
Drug: Diane‐35 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diane‐35 plus metformin (DM group)
Study: 29602978
Drug: Diane‐35 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diane‐35 plus orlistat plus metformin (DOM group)
Study: 27825638
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg)
Study: 25138333
Drug: Sustained care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained care (n = 198) with automated interactive voice response telephone calls and choice of free smoking cessation medication for up to 90 days
Study: 16328419
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy and exercise with physical therapy agents in both groups
Study: 11219963
Drug: Triazolam (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.125 mg/70 kg)
Study: 8637993
Drug: Oral CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral CT contrast agents
Study: 20410089
Drug: n-3 long-chain
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 long-chain polyunsaturated fatty acid supplementation (200 mg EPA plus 500 mg DHA)
Study: 16231596
Drug: Intensive Treatment
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive Treatment Group (n=6 students) received the basic module plus 'Student-related training in Contingency Management' (total 14h)
Study: 16377322
Drug: Diphenhydramine 50
Normalized name: diphenhydrAMINE 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 50 mg intravenously
Study: 24512
Drug: Diphenhydramine 50
Normalized name: diphenhydrAMINE 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 50 mg orally
Study: 24512
Drug: Diphenhydramine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (both IV and oral)
Study: 31770296
Drug: Pregabalin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (2 mg/kg twice daily for 5 days post-surgery)
Study: 28112467
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) with drug-eluting stents (DES)
Study: 15203432
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) for six weekly one-hour sessions
Study: 9935252
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg trovafloxacin orally before surgery as a single dose
Study: 9935252
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg trovafloxacin orally before surgery as multiple doses
Study: 7860441
Drug: Therapeutic administration
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic administration of platelet concentrates
Study: 7860441
Drug: Prophylactic administration
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic administration of platelets
Study: 3354496
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of calcium absorption
Study: 8324023
Drug: roxithromycin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin (300 mg daily for 10 days)
Study: 8324023
Drug: amoxicillin-clavulanic
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxicillin-clavulanic
Study: 25018037
Drug: Abiraterone 1000
Normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone 1000 mg plus prednisone 5 mg by mouth twice daily
Study: 19120893
Drug: Tailored eradication
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tailored eradication therapy (PPI/AC for CAM-sensitive strains, PPI/AM for CAM-resistant strains)
Study: 16634738
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy for 6 months
Study: 16634738
Drug: Anticoagulant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant therapy (6 weeks or 6 months)
Study: 12711662
Drug: Group treatment
Normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group treatment (2 weeks + 4 out-patient sessions)
Study: 8923126
Drug: SSRIs (Fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs (Fluoxetine 20 mg once a day and Fluvoxamine 100 mg twice a day)
Study: 1673110
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg (b.i.d.)
Study: 1673110
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg (b.i.d.)
Study: 28423524
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (80 mg/m2 for 12 weeks)
Study: 9344199
Drug: Combination clindamycin/benzoyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination clindamycin/benzoyl peroxide gel
Study: 9344199
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide gel
Study: 25172376
Drug: Twice-daily co-trimoxazole
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily co-trimoxazole for 3 days
Study: 25172376
Drug: Once-daily co-trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily co-trimoxazole for 5 days
Study: 23740801
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg ocrelizumab
Study: 23740801
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ocrelizumab
Study: 18805718
Drug: Immediate implants
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implants augmented with autogenous bone graft
Study: 16466172
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal treatment for clearing heat, detoxicating and nourishing Yin (CHM)
Study: 9771244
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone
Study: 8777828
Drug: Oral theophylline
Normalized name: theophylline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline (10-20 mg/l blood levels)
Study: 30114246
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of detemir (1.6 U/kg body weight)
Study: 15719743
Drug: Zhibituo treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhibituo treatment
Study: 6228913
Drug: Aspirin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1 g/day)
Study: 6401878
Drug: Aspirin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1 g/day) and Aspirin (1 g/day) + Dipyridamole (225 mg/day) combined
Study: 348379
Drug: Diflunisal, 250
Normalized name: Diflunisal, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal, 250 mg twice daily
Study: 17311843
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate/salmeterol combination treatment
Study: 9719081
Drug: Low-dose intensity
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intensity
Study: 9719081
Drug: Moderate-dose intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose intensity
Study: 9719081
Drug: High-dose intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intensity
Study: 7715258
Drug: Continuous perfusion
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous perfusion of NTG at 2 mg/h (Group A)
Study: 7715258
Drug: Continuous perfusion
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous perfusion of NTG at 4 mg/h (Group B)
Study: 336057
Drug: Rheumon Gel
Normalized name: Rheumox
DrugBank: Etofenamate (DB08984)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rheumon Gel (etofenamate)
Study: 144509
Drug: Ointment I
Normalized name: OINTMENT IN PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment I (2-hydroxyethyl salicylate and p-menthan-3-ol)
Study: 144509
Drug: Ointment II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment II (3,5-dioxo-1,2-diphenyl-4-n-butylpyrazolidine)
Study: 17761978
Drug: Thalidomide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (400 mg daily)
Study: 24830937
Drug: MgCl2 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgCl2 5% solution (30 mL, equivalent to 382 mg of magnesium)
Study: 23710976
Drug: Methylphenidate or
Normalized name: methylphenidate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate or dexamphetamine (titrated doses)
Study: 22009030
Drug: Uninterrupted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uninterrupted treatment (arm A)
Study: 8976637
Drug: Testosterone propionate
Normalized name: Testosterone Propionate
DrugBank: Testosterone propionate (DB01420)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone propionate 50 mg intramuscularly every two weeks for one year
Study: 25437223
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose (500 mg)
Study: 20436978
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg acetaminophen orally
Study: 11900816
Drug: Progesterone treatment
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone treatment (200 mg dose)
Study: 10086963
Drug: No antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiarrhythmic therapy (Control)
Study: 5389
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg fluoride - 42 mg sucrose tablets
Study: 5389
Drug: Fluoride-free, sucrose-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride-free, sucrose-containing placebo tablets
Study: 22706585
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of Clopidogrel and Rabeprazole
Study: 19935143
Drug: Cardiac rehabilitation
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac rehabilitation with relaxation therapy (CPRT)
Study: 1972487
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (75 mg daily)
Study: 12215748
Drug: Low-dose sublingual
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sublingual isosorbide dinitrate (2.5 mg) during HUTT
Study: 12215748
Drug: Isoproterenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusion (1 to 3 µg/min) during HUTT
Study: 9694469
Drug: Injection rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection rate of 2 ml/sec
Study: 9694469
Drug: Injection rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection rate of 3 ml/sec
Study: 9694469
Drug: Injection rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection rate of 4 ml/sec
Study: 11452241
Drug: Dapsone (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone (daily and weekly dosing)
Study: 30919036
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g myo-Inositol combined with 400 mg folic acid
Study: 30919036
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg folic acid
Study: 27098499
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose (2 mL of 88% sucrose solution)
Study: 27098499
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 mL of placebo solution)
Study: 17641250
Drug: Transdermal GTN
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal GTN 1.2 mg for 2 hours
Study: 17641250
Drug: Pentaerythrityl tetranitrate
Normalized name: pentaerythrityl tetraethylhexanoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaerythrityl tetranitrate (PETN) 80 mg
Study: 30507875
Drug: Acetaminophen (200 mg/kg/d)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (200 mg/kg/d)
Study: 25415807
Drug: ZS‐9 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZS‐9 (2.5 g)
Study: 25415807
Drug: ZS‐9 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZS‐9 (5 g)
Study: 25415807
Drug: ZS‐9 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZS‐9 (10 g)
Study: 25415807
Drug: ZS‐9 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZS‐9 (5 g) during maintenance phase
Study: 25415807
Drug: ZS‐9 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZS‐9 (10 g) during maintenance phase
Study: 10618526
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose for children with anti‐HBsAg concentrations below 10 mUI/ml
Study: 10618526
Drug: Recombinant HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant HBV vaccine administered earlier
Study: 21839625
Drug: Ciclesonide 80
Normalized name: CICLESONIDE 80MCG 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide 80 μg
Study: 21839625
Drug: Ciclesonide 160
Normalized name: CICLESONIDE 160MCG 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide 160 μg
Study: 26001339
Drug: Ciclesonide 80
Normalized name: CICLESONIDE 80MCG 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide 80 μg and 160 μg
Study: 25034652
Drug: Multidisciplinary pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary pain therapy for 4 weeks
Study: 12409326
Drug: Gemcitabine 1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,250 mg/m(2) days 1 and 8 plus cisplatin 75 mg/m(2) day 2 every 21 days (GC arm)
Study: 12409326
Drug: Paclitaxel 225
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 225 mg/m(2) (3‐hour infusion) then carboplatin (AUC 6 mg/mL x min) on day 1 every 21 days (PCb arm)
Study: 12409326
Drug: Vinorelbine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m(2)/wk for 12 weeks then every other week plus cisplatin 100 mg/m(2) day 1 every 28 days (VC arm)
Study: 10334422
Drug: Oral coenzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral coenzyme Q for 3 months
Study: 30159300
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - COPD conventional medications and walking on paved surfaces
Study: 20143247
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of pure oxygen
Study: 20143247
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of air (placebo)
Study: 17936285
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist administration (early studies)
Study: 17936285
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist administration (later studies)
Study: 21820233
Drug: Postoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative administration of oral pregabalin 75 mg
Study: 14609895
Drug: 30% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% sucrose intraoral administration
Study: 10674411
Drug: No drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drugs (Control)
Study: 9172968
Drug: Maprotiline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (75 mg/day)
Study: 25670636
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin treatment (control group)
Study: 8047827
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg twice daily
Study: 4089577
Drug: Highly purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly purified duck embryo rabies vaccine (PDEV)
Study: 28318872
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone injection into the pterygomandibular space